Aridis Pharmaceuticals Inc.
News
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
Globe Newswire LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Companys proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is ...\n more…
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
Globe Newswire QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening ...\n more…
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
Accesswire ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money...\n more…
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
Globe Newswire LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-...\n more…
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Short Interest Down 41.9% in May
Zolmax Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS Get Rating) was the recipient of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 439,700 shares, a drop of 41.9% from the May 15th total of 756,200 shares. Based on an average daily volume of 3,920...\n more…
Short Interest in Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Drops By 41.9%
Ticker Report Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS Get Rating) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 439,700 shares, a decline of 41.9% from the May 15th total of 756,200 shares. Based on an average trading volume of 3,...\n more…